Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1214Neoplasms 1024Carcinoma, Non-Small-Cell Lung 851Prostatic Neoplasms 683Colorectal Neoplasms 608Lung Neoplasms 575Neoplasm Metastasis 431Multiple Myeloma 420Leukemia, Myeloid, Acute 394Pancreatic Neoplasms 371Ovarian Neoplasms 359Melanoma 317Carcinoma, Hepatocellular 284Recurrence 274Squamous Cell Carcinoma of Head and Neck 272Brain Neoplasms 264Glioblastoma 245Head and Neck Neoplasms 241Stomach Neoplasms 236Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Carcinoma, Renal Cell 225Lymphoma 221Triple Negative Breast Neoplasms 216Endometrial Neoplasms 207Hematologic Neoplasms 206Urinary Bladder Neoplasms 195Lymphoma, Non-Hodgkin 194Sarcoma 189Uterine Cervical Neoplasms 187Glioma 187

Interventions

capivasertib 2Fulvestrant 2ribociclib 1palbociclib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer × 90 days × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡